Semaglutide's effect on inflammation in type 2 diabetes
Treatments studied
Part of Hormones & metabolism clinical trials.
This study tests whether the diabetes medication semaglutide can reduce inflammation and improve blood vessel health in people with type 2 diabetes who have no significant heart artery blockages. If you have diabetes and are at moderate to high heart risk but haven't had heart problems, this could help understand the medicine's extra benefits beyond blood sugar control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have type 2 diabetes and are between 18 and 85 years old.
- You have no known heart artery blockages of 50% or more (confirmed by a heart scan within the past 2 years).
- Your heart pumping ability is at least 50% (normal or near normal).
- You haven't taken semaglutide or similar GLP-1 medications before.
- Your kidneys are working well (no moderate to severe kidney disease).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether semaglutide can improve heart and blood-vessel outcomes in people with type 1 diabetes who use an insulin pump or automated insulin delivery. It may help reduce cardiovascular risks, but you must meet several health and medication-safety requirements.
This study compares a weekly injection called semaglutide with a calorie-restricted diet to see which helps control blood sugar better. If you have just been diagnosed with type 2 diabetes and have overweight, this trial might help you choose a treatment path.
This study tests whether semaglutide, a medicine that helps control blood sugar and reduce weight, can benefit adults with type 1 diabetes who are overweight. If you qualify, you may receive the drug or a placebo, and the study team will monitor your health closely.
This study tests how well a diabetes medication called semaglutide works when prescribed in everyday clinical practice in Argentina. Semaglutide comes in two forms—a pill or an injection—and the study tracks how much it lowers blood sugar over one year.
This study tests a new medication called semaglutide (similar to Ozempic) in people with type 2 diabetes who are already taking metformin. It aims to see if this medication improves blood sugar control and may also help with weight loss.
This study tests a new medication called Bofanglutide (an injectable drug, similar to others in its class) to see if it can help control blood sugar in adults with type 2 diabetes. It may also help with weight management. Participants will continue taking their current diabetes medication (metformin).
Hear when a new T2DM (Type 2 Diabetes Mellitus) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.